AR079876A1 - Gonadotrofina corionica humana recombinante con alto contenido de acido sialico y uso farmaceutico de la misma - Google Patents

Gonadotrofina corionica humana recombinante con alto contenido de acido sialico y uso farmaceutico de la misma

Info

Publication number
AR079876A1
AR079876A1 ARP100103608A ARP100103608A AR079876A1 AR 079876 A1 AR079876 A1 AR 079876A1 AR P100103608 A ARP100103608 A AR P100103608A AR P100103608 A ARP100103608 A AR P100103608A AR 079876 A1 AR079876 A1 AR 079876A1
Authority
AR
Argentina
Prior art keywords
sialic acid
gonadotrophine
same
recombinant human
high content
Prior art date
Application number
ARP100103608A
Other languages
English (en)
Spanish (es)
Original Assignee
Ferring Int Ct Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Int Ct Sa filed Critical Ferring Int Ct Sa
Publication of AR079876A1 publication Critical patent/AR079876A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/59Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1081Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/005Glycopeptides, glycoproteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/99Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ARP100103608A 2009-10-05 2010-10-05 Gonadotrofina corionica humana recombinante con alto contenido de acido sialico y uso farmaceutico de la misma AR079876A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09252360 2009-10-05

Publications (1)

Publication Number Publication Date
AR079876A1 true AR079876A1 (es) 2012-02-29

Family

ID=41471027

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP100103608A AR079876A1 (es) 2009-10-05 2010-10-05 Gonadotrofina corionica humana recombinante con alto contenido de acido sialico y uso farmaceutico de la misma
ARP220101408A AR125991A2 (es) 2009-10-05 2022-05-27 Preparación farmacéutica

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP220101408A AR125991A2 (es) 2009-10-05 2022-05-27 Preparación farmacéutica

Country Status (25)

Country Link
US (5) US8975226B2 (online.php)
EP (2) EP2486051B1 (online.php)
JP (6) JP6176924B2 (online.php)
KR (7) KR102489143B1 (online.php)
CN (1) CN107050434B (online.php)
AR (2) AR079876A1 (online.php)
AU (1) AU2010304922B2 (online.php)
BR (1) BR112012007990A2 (online.php)
CA (1) CA2776790A1 (online.php)
DK (1) DK2486051T3 (online.php)
ES (2) ES3036152T3 (online.php)
HR (1) HRP20200941T1 (online.php)
HU (1) HUE050793T2 (online.php)
IL (3) IL218548A (online.php)
IN (1) IN2012DN02073A (online.php)
JO (1) JOP20200039A1 (online.php)
LT (1) LT2486051T (online.php)
MX (1) MX2012003951A (online.php)
PL (1) PL2486051T3 (online.php)
PT (1) PT2486051T (online.php)
RS (1) RS60413B1 (online.php)
RU (2) RU2724528C2 (online.php)
SI (1) SI2486051T1 (online.php)
TW (2) TWI532495B (online.php)
WO (1) WO2011042688A1 (online.php)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
WO2012131306A1 (en) 2011-03-31 2012-10-04 Ferring B.V. Pharmaceutical preparation
AR090095A1 (es) * 2011-06-06 2014-10-22 Ferring Bv Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
WO2013093760A2 (en) * 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
SG10201704774VA (en) 2012-12-10 2017-07-28 Seikagaku Kogyo Co Ltd Novel recombinant factor c and method for producing the same, and method for measuring endotoxin
CN107429237B (zh) * 2014-12-22 2021-09-28 豪夫迈·罗氏有限公司 Cmp依赖性的唾液酸酶活性
EA034022B1 (ru) * 2015-04-24 2019-12-19 Ферринг Б.В. Способ получения гонадотропина
MX381279B (es) 2015-06-26 2025-03-12 Ferring Bv Métodos de purificación y/o inactivación viral.
US20210038694A1 (en) 2018-04-30 2021-02-11 Ferring B.V. Composition for controlled ovarian stimulation
US20210244821A1 (en) * 2020-02-05 2021-08-12 Novartis Ag Cho cell expressed het il-15
CN116199742B (zh) * 2022-07-06 2025-01-24 华兰基因工程有限公司 一种重组人绒毛膜促性腺激素Fc融合蛋白制备方法
KR102821987B1 (ko) * 2024-10-24 2025-06-26 에이디텍 주식회사 베타 코어 단편 hCG를 유효성분으로 포함하는 난임 치료용 조성물

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4840896A (en) * 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
DK49987A (da) 1987-01-30 1988-07-31 Nordisk Gentofte Fremgangsmaade til behandling af infertilitet og middel til anvendelse ved fremgangsmaaden
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
ES2166841T3 (es) * 1995-03-21 2002-05-01 Applied Research Systems Formulaciones liquidas de hcg.
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
BR9810478A (pt) 1997-06-25 2000-09-12 Applied Research Systems Análogos de hormÈnio glicoproteìna reticulados por dissulfeto e sua preparação e utilização
US6500627B1 (en) 1998-02-03 2002-12-31 The Trustees Of Columbia University In The City Of New York Methods for predicting pregnancy outcome in a subject by HCG assay
WO2003050286A1 (en) * 2001-10-29 2003-06-19 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
EP1176976B2 (en) 1999-05-07 2015-10-21 Laboratoires Serono SA Use of lh administered in mid- or late-follicular phase for the treatment of anovulatory women
JP4588960B2 (ja) 2000-02-22 2010-12-01 メルク セローノ ソシエテ アノニム hCGの精製方法及び本法により精製した組換えhCG
EP1425032A2 (en) 2001-09-12 2004-06-09 Applied Research Systems ARS Holding N.V. USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION
UA87433C2 (ru) * 2001-10-22 2009-07-27 Еплайд Рісьорч Системз Ерс Холдінг Н.В. Гонадотропины для стимулирования фолликулогенеза
CN100347306C (zh) * 2001-10-29 2007-11-07 克鲁塞尔荷兰公司 生产具有预定的翻译后修饰的蛋白质的方法和手段
CN1374525A (zh) * 2001-12-31 2002-10-16 陕西超英生物医学研究开发有限公司 一种抗体芯片、其制备技术及其检测方法
EA200501548A1 (ru) 2003-04-01 2006-02-24 Апплайд Резеч Системз Арс Холдинг Н.В. Ингибиторы фосфодиэстераз при бесплодии
NZ542586A (en) * 2003-04-09 2009-11-27 Biogenerix Ag Method of forming a covalent conjugate between a G-CSF peptide and PEG
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
JP4518464B2 (ja) 2003-06-30 2010-08-04 ミヨシ油脂株式会社 紙類処理剤及び紙類
EP1654353B1 (en) * 2003-08-18 2013-05-22 Glycotope GmbH Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses threreof
EP1711834B1 (en) 2004-02-04 2010-08-04 Centre National De La Recherche Scientifique Process for screening glycoform-specific antibodies
EP1725673A1 (en) * 2004-02-13 2006-11-29 Glycotope Gmbh Sialytated glycoproteins-process conditions and an efficient method for their production
AU2006222187A1 (en) * 2005-03-11 2006-09-14 Fresenius Kabi Deutschland Gmbh Production of bioactive glycoproteins from inactive starting material by conjugation with hydroxyalkylstarch
DE112006002122B4 (de) * 2005-08-15 2016-09-22 Continental Automotive Systems, Inc. ( n. d. Ges. d. Staates Delaware ) Dieselabgas-Kohlenwasserstoff-Dosierventil für Fahrzeuge
RU2309411C2 (ru) * 2005-11-24 2007-10-27 Ростовский НИИ акушерства и педиатрии МЗ РФ Способ отбора пациенток с синдромом "пустых" фолликулов для проведения программы эко и пэ донорскими ооцитами
KR100809945B1 (ko) * 2006-02-01 2008-03-05 대한민국 인체장내정상세균총 특이반응 dna칩 및 이를 이용한인체장내정상세균총의 변화에 의한 인체 위해성의 평가방법
US20080242607A1 (en) * 2006-07-21 2008-10-02 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US8969532B2 (en) * 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
WO2012131306A1 (en) * 2011-03-31 2012-10-04 Ferring B.V. Pharmaceutical preparation
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض

Also Published As

Publication number Publication date
IL218548A (en) 2017-03-30
HRP20200941T1 (hr) 2020-09-18
JP6310440B2 (ja) 2018-04-11
JOP20200039A1 (ar) 2022-10-30
JP6580104B2 (ja) 2019-09-25
RU2016118236A (ru) 2018-10-29
ES3036152T3 (en) 2025-09-15
EP3611185A1 (en) 2020-02-19
US12234272B2 (en) 2025-02-25
JP2016074680A (ja) 2016-05-12
KR20170133531A (ko) 2017-12-05
CN107050434B (zh) 2021-07-27
IL218548A0 (en) 2012-05-31
RU2588650C2 (ru) 2016-07-10
US20220340634A1 (en) 2022-10-27
LT2486051T (lt) 2020-07-10
JP2018076296A (ja) 2018-05-17
CA2776790A1 (en) 2011-04-14
JP7292153B2 (ja) 2023-06-16
KR20210141771A (ko) 2021-11-23
KR102489143B1 (ko) 2023-01-13
KR20230012104A (ko) 2023-01-25
JP7196244B2 (ja) 2022-12-26
KR101804479B1 (ko) 2017-12-05
RS60413B1 (sr) 2020-07-31
EP3611185B1 (en) 2025-04-30
IN2012DN02073A (online.php) 2015-08-21
DK2486051T3 (da) 2020-06-22
AU2010304922A1 (en) 2012-03-29
US20180030107A1 (en) 2018-02-01
KR20120094909A (ko) 2012-08-27
TWI604850B (zh) 2017-11-11
PL2486051T3 (pl) 2020-09-07
US20130023476A1 (en) 2013-01-24
US20140249082A1 (en) 2014-09-04
ES2798258T3 (es) 2020-12-10
RU2016118236A3 (online.php) 2019-09-18
HUE050793T2 (hu) 2021-01-28
US9676835B2 (en) 2017-06-13
IL250733A0 (en) 2017-04-30
KR102213154B1 (ko) 2021-02-05
BR112012007990A2 (pt) 2017-07-25
EP2486051A1 (en) 2012-08-15
KR20190028823A (ko) 2019-03-19
IL267556A (en) 2019-08-29
JP2013506708A (ja) 2013-02-28
KR20190067256A (ko) 2019-06-14
JP6176924B2 (ja) 2017-08-09
TWI532495B (zh) 2016-05-11
KR20210014767A (ko) 2021-02-09
CN107050434A (zh) 2017-08-18
JP2021176867A (ja) 2021-11-11
US11292824B2 (en) 2022-04-05
US10526390B2 (en) 2020-01-07
TW201113030A (en) 2011-04-16
RU2012112907A (ru) 2013-11-10
MX2012003951A (es) 2012-05-29
AR125991A2 (es) 2023-08-30
US8975226B2 (en) 2015-03-10
PT2486051T (pt) 2020-06-17
JP2023075144A (ja) 2023-05-30
WO2011042688A1 (en) 2011-04-14
SI2486051T1 (sl) 2020-08-31
CN102549011A (zh) 2012-07-04
RU2724528C2 (ru) 2020-06-23
TW201632198A (zh) 2016-09-16
US20200247863A1 (en) 2020-08-06
AU2010304922B2 (en) 2014-11-06
IL250733B (en) 2019-07-31
KR101987982B1 (ko) 2019-06-11
EP2486051B1 (en) 2020-03-25
JP2020000246A (ja) 2020-01-09

Similar Documents

Publication Publication Date Title
EA201170879A1 (ru) Полипептиды с ксиланазной активностью
NZ596037A (en) Fgf21 mutants and uses thereof
NZ596849A (en) Serum amyloid p derivatives and their preparation and use
NZ598348A (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
AR071479A1 (es) Hormona foliculo estimulante recombinante (rfsh) con union de acido sialico en a2,3 y a2,6
PH12012501895A1 (en) Long-acting formulations of insulins
SG178797A1 (en) Oligosaccharide chain added glp-1 peptide
EA201170993A1 (ru) Удлиненные рекомбинантные полипептиды и содержащие их композиции
AR092456A1 (es) Proteinas de fusion para el tratamiento de un sindrome metabolico
NZ597580A (en) Polypeptides selective for alpha.v.beta.3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof
NZ715203A (en) Heparan sulphates
BR112013032630A2 (pt) polipeptídeo heterodimerizado
NZ604877A (en) Improved recombinant human follicle-stimulating hormone
BR112014014913A2 (pt) mutante prongf e método de preparação de uma beta-ngf humana biologicamente ativa
BR112012027545A8 (pt) Composto, composição farmacêutica, uso da composição farmacêutica e uso de um composto
MY151184A (en) A polypeptide complex comprising non-peptidyl polymer having three functional ends
NZ609959A (en) Modified factor ix polypeptides and uses thereof
IN2012DN00377A (online.php)
PE20142432A1 (es) Usos terapeuticos de proteinas del factor de crecimiento del fibroblasto 21
CO2017006870A2 (es) Métodos de producción de polipéptidos de hormona de crecimiento modificada por ctp
MX2024015741A (es) Alfa-glucosidasa acida humana recombinante
EP4613284A3 (en) Treatment of diabetes mellitus by long-acting formulations of insulins
PE20130379A1 (es) Metodos para el tratamiento de las ulceras del pie diabetico
MY169650A (en) Crystalline recombinant interferon with altered spatial configuration,three-dimensional structure and uses thereof
NZ590469A (en) Treatment of rheumatoid arthritis with human beta defensins (1-4)

Legal Events

Date Code Title Description
FC Refusal